(0.10%) 5 522.50 points
(0.12%) 39 893 points
(0.22%) 19 794 points
(-0.01%) $81.62
(0.53%) $2.83
(-0.30%) $2 337.40
(0.12%) $29.56
(0.28%) $1 004.60
(0.00%) $0.931
(-0.03%) $10.53
(-0.02%) $0.788
(-0.85%) $87.25
0.85% $ 3.56
Live Chart Being Loaded With Signals
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company\'s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia...
Stats | |
---|---|
Dzisiejszy wolumen | 31 931 |
Średni wolumen | 35 256 |
Kapitalizacja rynkowa | 19.53M |
EPS | $-0.660 ( Q3 | 2023-11-06 ) |
Last Dividend | $1 801.73 ( 1980-05-12 ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.270 (7.58%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-26 | Devall Christopher Franklin | Buy | 7 000 | Common Stock |
2023-12-26 | Wool Kyle Michael | Buy | 5 000 | Common Stock |
2023-12-21 | Wool Kyle Michael | Buy | 630 050 | Common Stock |
2023-12-20 | Hayes Anthony | Buy | 70 000 | Common Stock |
2023-12-12 | Hayes Anthony | Buy | 2 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 6 932 818 | Sell: 0 |
Wolumen Korelacja
AIkido Pharma Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
GNACW | 0.901 |
10 Najbardziej negatywne korelacje | |
---|---|
DAOO | -0.958 |
GNAC | -0.946 |
IIII | -0.935 |
SHQA | -0.911 |
SCOA | -0.905 |
HCIC | -0.901 |
HCII | -0.894 |
HIIIU | -0.883 |
HCICU | -0.851 |
HIII | -0.847 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
AIkido Pharma Inc. Korelacja - Waluta/Towar
AIkido Pharma Inc. Finanse
Annual | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-5.60 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-5.60 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-4.34 |
FY | 2020 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-7.47 |
Financial Reports:
No articles found.
AIkido Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1 544.34 | 1978-05-15 |
Last Dividend | $1 801.73 | 1980-05-12 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $5 147.79 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.53 | -- |
Div. Sustainability Score | 1.053 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1978 | $0 | 0.00% |
1979 | $0 | 0.00% |
1980 | $0 | 0.00% |
1981 | $0 | 0.00% |
1982 | $0 | 0.00% |
1983 | $0 | 0.00% |
1984 | $0 | 0.00% |
1985 | $0 | 0.00% |
1986 | $0 | 0.00% |
1987 | $0 | 0.00% |
1988 | $0 | 0.00% |
1989 | $0 | 0.00% |
1990 | $0 | 0.00% |
1991 | $0 | 0.00% |
1992 | $0 | 0.00% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
12 May 1980 | $1 801.73 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
14 May 1979 | $1 801.73 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
15 May 1978 | $1 544.34 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -19.43 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.318 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.306 | 1.500 | -4.51 | -6.76 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 20.26 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 16.48 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.55 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00650 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 36.16 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -3.04 | 2.00 | -1.012 | -2.02 | [0 - 30] |
freeCashFlowPerShareTTM | -3.10 | 2.00 | -1.552 | -3.10 | [0 - 20] |
debtEquityRatioTTM | 0.00704 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -23.01 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -39.50 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0164 | 0.800 | -3.22 | -2.58 | [0.5 - 2] |
Total Score | 1.053 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.947 | 1.000 | -0.197 | 0 | [1 - 100] |
returnOnEquityTTM | -0.306 | 2.50 | -2.90 | -6.76 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -3.10 | 2.00 | -1.035 | -3.10 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -3.04 | 2.00 | -1.012 | -2.02 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0144 | 1.500 | -3.43 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -15.70 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.67 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company\'s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej